- Home
- NRXS vs MIST Comparison
NRXS vs MIST Comparison
Compare NRXS & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | MIST |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 95.3M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NRXS | MIST |
|---|---|---|
| Price | $7.64 | $0.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $11.00 | $5.86 |
| AVG Volume (30 Days) | 140.1K | ★ 971.5K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,569,282.00 | N/A |
| Revenue This Year | $132.54 | $147.62 |
| Revenue Next Year | $138.55 | $476.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.89 | N/A |
| 52 Week Low | $2.21 | $0.69 |
| 52 Week High | $9.33 | $3.06 |
Technical Indicators
Market Signals| Indicator | NRXS | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 30.94 |
| Support Level | $6.60 | N/A |
| Resistance Level | $7.75 | $1.42 |
| Average True Range (ATR) | 0.45 | 0.06 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 73.17 | 8.99 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.